The wholly-owned step-down subsidiary of Aurobindo Pharma, CuraTeQ Biologics s.r.o., has secured a marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to market Dazublys, a trastuzumab biosimilar version, the company informed the stock exchanges in a filing.
